ProMIS Neurosciences Inc. financial data

Symbol
PMN on Nasdaq
Industry
Pharmaceutical Preparations
Location
Suite 200, 1920 Yonge Street, Toronto, Ontario, Canada
State of incorporation
Canada (Federal Level)
Fiscal year end
December 31
Former names
AMORFIX LIFE SCIENCES LTD (to 11/3/2014)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 242 % +166%
Debt-to-equity 388 %
Return On Equity -25.5 % -104%
Return On Assets -5.23 % +97.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.7M shares +73.1%
Common Stock, Shares, Outstanding 32.7M shares +76.5%
Entity Public Float 29.7M USD
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 30M shares +143%
Weighted Average Number of Shares Outstanding, Diluted 30.1M shares +143%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 8.54M USD -29.1%
General and Administrative Expense 6.16M USD -10.3%
Operating Income (Loss) -14.7M USD +22.3%
Nonoperating Income (Expense) 14.1M USD +602%
Net Income (Loss) Attributable to Parent -563K USD +96.7%
Earnings Per Share, Basic -0.04 USD/shares +97.9%
Earnings Per Share, Diluted -0.04 USD/shares +97.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 21.5M USD +27.7%
Assets, Current 24.5M USD +37.3%
Property, Plant and Equipment, Net 321 USD -93.1%
Intangible Assets, Net (Excluding Goodwill) 18K USD -17.1%
Assets 24.5M USD +37.1%
Accounts Payable, Current 1.58M USD -81.3%
Accrued Liabilities, Current 1.06M USD -26.2%
Liabilities, Current 2.64M USD -73.3%
Liabilities 17.2M USD +55%
Accumulated Other Comprehensive Income (Loss), Net of Tax -371K USD 0%
Retained Earnings (Accumulated Deficit) -90.4M USD -0.63%
Stockholders' Equity Attributable to Parent 7.27M USD +7.67%
Liabilities and Equity 24.5M USD +37.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.3M USD -302%
Net Cash Provided by (Used in) Financing Activities 190K USD
Common Stock, Shares, Issued 32.7M shares +76.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.1M USD -297%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 21.5M USD +27.7%
Deferred Tax Assets, Valuation Allowance 27.7M USD +15.4%
Deferred Tax Assets, Gross 27.7M USD +15.4%
Depreciation 4.69K USD -81.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -388K USD +97.7%
Property, Plant and Equipment, Gross 80.3K USD -4.45%
Deferred Tax Assets, Operating Loss Carryforwards 21.2M USD +20.1%
Preferred Stock, Shares Issued 0 shares -100%
Preferred Stock, Shares Authorized 70M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 98.1M USD +1.12%
Preferred Stock, Shares Outstanding 0 shares -100%
Amortization of Intangible Assets 4.99K USD -6.38%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 73.3K USD -86.4%
Interest Expense 76.8K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares